Castiglione, Monica

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2009 | 2008 | 2005 | 2001 | 2000 | 1998 | 1997 | 1996


Viale, G.; Giobbie-Hurder, A.; Gusterson, B. A.; Maiorano, E.; Mastropasqua, M. G.; Sonzogni, A.; Mallon, E.; Colleoni, M.; Castiglione-Gertsch, M.; Regan, M. M.; Price, K. N.; Brown, R. W.; Golouh, R.; Crivellari, D.; Karlsson, P.; Öhlschlegel, C.; Gelber, R. D.; Goldhirsch, A.; Coates, A. S. (2009). Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Annals of oncology, 21(2), pp. 245-254. Oxford University Press 10.1093/annonc/mdp317


Viale, Giuseppe; Regan, Meredith M.; Mastropasqua, Mauro G.; Maffini, Fausto; Maiorano, Eugenio; Colleoni, Marco; Price, Karen N.; Golouh, Rastko; Perin, Tiziana; Brown, R. W.; Kovács, Anikó; Pillay, Komala; Öhlschlegel, Christian; Gusterson, Barry A.; Castiglione-Gertsch, Monica; Gelber, Richard D.; Goldhirsch, Aron; Coates, Alan S. (2008). Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. Journal of the National Cancer Institute JNCI, 100(3), pp. 207-212. Oxford University Press 10.1093/jnci/djm289

Ravaioli, A.; Monti, F.; Regan, M. M.; Maffini, F.; Mastropasqua, M. G.; Spataro, V.; Castiglione-Gertsch, Monica; Panzini, I.; Gianni, L.; Goldhirsch, A.; Coates, A.; Price, K. N.; Gusterson, B. A.; Viale, G. (2008). p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Annals of oncology, 19(4), pp. 660-668. Oxford University Press 10.1093/annonc/mdm547

Francis, Prudence; Crown, John; Di Leo, Angelo; Buyse, Marc; Balil, Ana; Andersson, Michael; Nordenskjöld, Bo; Lang, Istvan; Jakesz, Raimund; Vorobiof, Daniel; Gutiérrez, Jorge; Van Hazel, Guy; Dolci, Stella; Jamin, Sophie; Bendahmane, Belguendouz; Gelber, Richard D.; Goldhirsch, Aron; Castiglione-Gertsch, Monica; Piccart-Gebhart, Martine (2008). Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02–98 Randomized Trial. Journal of the National Cancer Institute JNCI, 100(2), pp. 121-133. Oxford University Press 10.1093/jnci/djm287

Regan, M. M.; Pagani, O.; Walley, B.; Torrisi, R.; Perez, E. A.; Francis, P.; Fleming, G. F.; Price, K. N.; Thürlimann, B.; Maibach, R.; Castiglione-Gertsch, M.; Coates, A. S.; Goldhirsch, A.; Gelber, R. D. (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Annals of oncology, 19(7), pp. 1231-1241. Oxford University Press 10.1093/annonc/mdn037


Goss, Paul E.; Ingle, James N.; Martino, Silvana; Robert, Nicholas J.; Muss, Hyman B.; Piccart, Martine J.; Castiglione, Monica; Tu, Dongsheng; Shepherd, Lois E.; Pritchard, Kathleen I.; Livingston, Robert B.; Davidson, Nancy E.; Norton, Larry; Perez, Edith A.; Abrams, Jeffrey S.; Cameron, David A.; Palmer, Michael J.; Pater, Joseph L. (2005). Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. Journal of the National Cancer Institute JNCI, 97(17), pp. 1262-1271. Oxford University Press 10.1093/jnci/dji250


Aebi, S.; Castiglione-Gertsch, M. (2001). High-dose chemotherapy for ovarian cancer: Are we ready to go? Annals of oncology, 12(5), pp. 583-584. Oxford University Press 10.1023/A:1011134312452


Roth, A. D.; Maibach, R.; Martinelli, G.; Fazio, N.; Aapro, M. S.; Pagani, O.; Morant, R.; Borner, M. M.; Herrmann, R.; Honegger, H.; Cavalli, F.; Alberto, P.; Castiglione, M.; Goldhirsch, A. (2000). Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma. Annals of oncology, 11(3), pp. 301-306. Oxford University Press 10.1023/A:1008342013224


Goldhirsch, A.; Coates, A. S.; Castiglione-Gertsch, M.; Gelber, R. D. (1998). New treatments for breast cancer: Breakthroughs for patient care or just steps in the right direction? Annals of oncology, 9(9), pp. 973-976. Oxford University Press 10.1023/A:1008436810268

Borner, M. M.; Castiglione, M.; Bacchi, M.; Weber, Walter; Herrmann, R.; Fey, M. F.; Pagani, O.; Leyvraz, S.; Morant, R.; Pestalozzi, B.; Hanselmann, S.; Goldhirsch, A. (1998). The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Annals of oncology, 9(5), pp. 535-541. Oxford University Press 10.1023/A:1008270916325


Goldhirsch, A.; Gelber, R. D.; Castiglione, M.; O'Neill, A.; Thürlimann, B.; Rudenstam, C.-M; Lindtner, J.; Collins, J.; Forbes, J.; Crivellari, D.; Coates, A.; Cavalli, F.; Simoncini, E.; Fey, M. F.; Pagani, O.; Price, K.; Senn, H.-J. (1997). Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Annals of oncology, 8(8), pp. 751-756. Oxford University Press 10.1023/A:1008220301866


Thürlimann, B.; Beretta, K.; Bacchi, M.; Castiglione-Gertsch, M.; Goldhirsch, A.; Jungi, W. F.; Cavalli, F.; Senn, H.-J.; Fey, M.; Löhnert, T. (1996). First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Annals of oncology, 7(5), pp. 471-479. Oxford University Press 10.1093/oxfordjournals.annonc.a010635

Provide Feedback